Chinese Journal of Antituberculosis ›› 2013, Vol. 35 ›› Issue (4): 231-239.
Previous Articles Next Articles
LIU Er-yong, ZHOU Lin, CHENG Shi-ming
Received:
2013-01-23
Online:
2013-04-10
Published:
2013-07-02
Contact:
CHENG Shi-ming
E-mail:smcheng@chinatb.org
[1] World Health Organization. Global tuberculosis control 2011[R/OL]. Geneva:World Health Organization, 2012(2011-11-07)[2012-11-16]. http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf.[2] Lalvani A, Pareek M. A 100 year update on diagnosis of tuberculosis infection. Br Med Bull, 2010, 93:69-84.[3] Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med, 2006, 174(7):736-742.[4] World Health Organization. Global tuberculosis report 2012 [R/OL]. Geneva:WHO,2012(2012-10-10)[2012-11-16]. http://www.who.int/tb/publications/global_report/en/.[5] Bennett DE, Courval JM, Onorato I, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med,2008,177(3):348-355.[6] Yuan L. Compendium of latent tuberculosis infection(LTBI) prevalence rates in Canada. Ottawa:Public Health Agency of Canada, 2007.[7] Doocy SC, Todd CS, Llainez YB, et al. Population-based tuberculin skin testing and prevalence of tuberculosis infection in Afghanistan. World Health Popul,2008,10(1):44-53.[8] 全国结核病流行病学抽样调查技术指导组,全国结核病流行病学抽样调查办公室. 2000年全国结核病流行病学抽样调查报告. 中国防痨杂志, 2002, 24(2):65-108.[9] 中华人民共和国卫生部. 2000年全国结核病流行病学抽样调查资料汇编. 北京:人民卫生出版社,2003:204. [10] He GX, Wang LX, Chai SJ, et al,Risk factors associated with tuberculosis infection among health care workers in Inner Mongolia, China. Int J Tuberc Lung Dis, 2012, 16(11):1485-1491.[11] United States Department of Health and Human Services Centers for Disease Control and Prevention. Latent tuberculosis infection: a guide for primary health care providers[DB/OL]. Atlanta: United States Centers for Disease Control and Prevention, 2010(2010-11-24)[2012-11-16].http://www.cdc.gov/tb/publications/ltbi/pdf/TargetedLTBI.pdf.[12] Brosch R, Vincent V. Cutting-edge science and the future of tuberculosis control. Bull World Health Organ,2007,85(5):410-412.[13] 彭超,王洪海. 结核分枝杆菌潜伏感染诊断方法的新进展. 生物技术通讯,2010,21(1):107-111.[14] Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep, 2010, 59(RR-5):1-25.[15] Page KR, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med,2006,166(17):1863-1870.[16] Bright-Thomas R, Nandwani S, Smith J, et al. Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children. Arch Dis Child,2010,95(8):600-602.[17] Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med,2011,365(23):2155-2166.[18] 刘玉清,屠德华,安燕生,等. 大学生结核病控制的研究:(二)结核感染者的预防性治疗. 中国防痨杂志,2005,27(3):139-142.[19] 杨运亭,赵清芳,宁海燕,等. 家庭密切接触者结核感染的预防性治疗效果观察. 中国现代药物应用,2009,3(14):209-210.[20] Grant AD, Charalambous S, Fielding KL, et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA,2005,293(22):2719-2725.[21] Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med,2011,365(1):11-20.[22] Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis,2007,45(6):715-722.[23] Duarte R, Carvalho A, Correia A. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection. Public Health,2012,126(9):760-762.[24] Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med,2006,173(8):922-926.[25] Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet,2011,377(9777):1588-1598.[26] Jamison DT, Breman JG, Measham AR, et al. Disease control priorities in developing countries. 2nd ed. Washington: Disease Control Priorities Project Population Reference Bureau, 2006: 289-309.[27] United States Department of Health and Human Services, Centers for Disease and Control, National Center for HIV, STD, and TB Prevention. Core Curriculum on Tuberculosis:What the Clinician Should Know. 5th ed. Atlanta: United States Department of Health and Human Services, 2011:112-116.[28] Menzies D, Gardiner G, Farhat M, et al. Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int J Tuberc Lung Dis,2008,12(5):498-505.[29] International Union Against Tuberculosis and Lung Disease. Interventions for tuberculosis control and elimination. Paris:International Union Against Tuberculosis and Lung Disease,2002.[30] Menzies D, Al Jahdali H, Al Otaibi B. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res,2011,133:257-266.[31] International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ,1982,60(4):555-564.[32] Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis,1999,3(10):847-850.[33] Gao XF, Wang L, Liu GJ, et al. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Int J Tuberc Lung Dis,2006,10(10):1080-1090.[34] Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA,2000,283(11):1445-1450.[35] Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis,1992,145(1):36-41.[36] Centers for Disease Control and Prevention(CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep,2011,60(48):1650-1653.[37] Dye C. Practical preventive therapy for tuberculosis? N Engl J Med,2011,365(23):2230-2231.[38] 庄玉辉,李国利, 王国治. 母牛分枝杆菌制剂在结核病免疫治疗与预防应用的研究进展. 微生物学通报, 1995,22(2):108-109.[39] 刘元东,靳晓红,李子建, 等.结核菌感染者微卡菌苗预防作用的研究,中国防痨杂志,2000,22(4):220-221. |
[1] | JIN Hong-jian. The construction of tuberculosis prevention and control service system at county level in China needs to be strengthened urgently —— Comments and suggestions of an old tuberculosis control and prevention worker [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 896-902. |
[2] | ZHU Li-mei, CHEN Can-can, CHEN Wei, HU Xiao-guang, ZHANG Ya-nan, MA Jun-yang. To formulate prevention and control strategy for latent tuberculosis infection population in China [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 794-798. |
[3] | ZHANG Kai, SHEN Xiao-bing, TAO Li-feng, WEI Fen, CHEN Bao-wen, QIU Jing-jing, CHEN Wei, LU Jin-biao, ZHU Yin-meng, CHENG Xing, ZHONG Zai-xin, ZHAO Ai-Hua, PU Jiang. Establishment of quality standards for recombinant Mycobacterium tuberculosis fusion protein [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 814-820. |
[4] | CHEN Feng-fang, MA Jun, HUANG Jin, YIN Hong-yun, SHA Wei, YANG Guang-hong, FENG Yong-hong. Preliminary study on establishing the diagnostic model for smear negative tuberculosis and stage Ⅰ/Ⅱ sarcoidosis with hilar/mediastinal lymphadenopathy and positive T-SPOT.TB results [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 832-837. |
[5] | DUAN Li-ming, DING Chao, LIU Yu-gang, WEI Lin, GU Zhen-ning. Application value of video-assisted thoracoscopic surgery in the treatment of chronic tuberculous empyema [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 850-853. |
[6] | YANG Lu-qi, SHEN Ming-yi, SHA Wei, CHEN Ying-ying, WANG Ying. Research progress in immunoprotective mechanism of bacille Calmette-Guérin and vaccine development strategies [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 863-868. |
[7] | SHEN Xin, SHA Wei, LIU Jian-jun. Impact of coronavirus disease 2019 (COVID-19) on tuberculosis control and countermeasures in China [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 544-548. |
[8] | ZHANG Pei-ze, FU Liang, TAN Jie, WANG Yu-xiang, CHEN Tao, DENG Guo-fang. CT imaging characteristics of cured multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 558-562. |
[9] | ZHAO Ben-nan, LIU Da-feng, LIU Ya-ling, YANG Ming, LAN Li-juan, DU Qing. Clinical analysis of hypothyroidism after anti-tuberculosis treatment in patients with multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 465-471. |
[10] | LI Jin,GUO Xiao-qin,LI Yong,ZOU Jin-yan,LU Li-ping. Analysis on the effect of active screening of tuberculosis among local people aged 65 or older in Songjiang District of Shanghai in 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 353-359. |
[11] | GAO Qian,MEI Jian. Reflections on the prevention and control of tuberculosis among Chinese students [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 195-199. |
[12] | CHEN Zhen-hua,LIU Bin-bin,CHEN Zhong-nan,TAN Yun-hong. Establishment and preliminary evaluation of a diagnostic model for the new patients with pathogen-negative pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 266-271. |
[13] | MA Gai-xia,TIAN Li-ming,WANG Yu,QIU Lei,XUE Ling-na,LU Zhen-hui,ZHANG Hui-yong,GUO Xiao-yan. Systematic evaluation and meta-analysis of integrated traditional Chinese and western medicine in the treatment of MDR-PTB [J]. Chinese Journal of Antituberculosis, 2020, 42(2): 95-100. |
[14] | SUN Ming-lei, GUAN Li, ZHAO Juan, WANG Chen, ZOU Dan-dan, LIANG Li-bo. Legislative considerations on traffic travel of MDR-TB/XDR-TB patients from the perspective of infectious disease prevention and control [J]. Chinese Journal of Antituberculosis, 2020, 42(12): 1268-1271. |
[15] | GU Ji-xiu, LI Qing, MA ling, LI Yin-hua, WANG Dong-dong, SI Hong-yan. Application of next-generation sequencing technology in the diagnosis of drug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(11): 1203-1208. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||